Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medi...(tinuation due to lack of efficacy howeve...),Health
tinuation due to lack of efficacy, however, discontinuation due to adverse events was not significantly different across the three treatment groups (P = 0.66).
Adverse Events
Overall, the study showed that LY2140023 40mg, given twice daily, was found to be safe and well-tolerated, with most adverse events being mild to moderate in severity and not treatment-limiting. The most common treatment- emergent adverse events in the LY2140023 group were insomnia, affect lability (P = 0.038), nausea, headache, somnolence and blood creatine phosphokinase increase. The adverse event profile of LY2140023 did not include prolactin increase or worsening of extrapyramidal symptoms (EPS). Although mood lability seems to represent the most important potential adverse event, it should be noted that this outcome was observed primarily at one clinical site. In the olanzapine group, treatment-emergent adverse events included elevation in blood triglyceride levels (P = 0.005), insomnia, weight gain (P = 0.034), somnolence, akathisia, agitation and periodontitis (P = 0.03).
About LY2140023
LY2140023 is an investigational drug from Lilly, which is being developed as a new treatment option for schizophrenia. LY2140023 is an oral "prodrug," meaning it is devoid of intrinsic biological activity and, once administered, is metabolized to provide the active mGlu2/3 receptor agonist called LY404039. Most currently approved antipsychotic medications work by affecting the neurotransmitters dopamine or serotonin. For LY2140023, the active substance, LY404039, is thought to work by reducing the presynaptic release of another neurotransmitter, glutamate, in brain regions where mGlu2/3 receptors are expressed. Further studies are planned or are ongoing to learn more about the safety and effectiveness, including determining an optimal therapeutic dose for LY2140023.
About Olanzapine
Olanzapine is marketed by Lilly as Zyprexa. Zyprexa is indicated in the
United States f
'/>"/>
| SOURCE Eli Lilly and Company Copyright©2007 PR Newswire. All rights reserved |
Related medicine news :
1. New Drug Application Submitted for Investigational Antibiotic Doripenem
2. Astrazenecas Investigational Cancer Therapies Revealed at ASCO
3. Investigational Drug Being Pursued for the Treatment of Ischaemic Stroke
4. Novel Investigational Drug May Help American Women Suffering from Breast Pain
5. Effective And Economical Agent For Anthrax
6. New target for antidiabetic agents identified
7. Gold Nanoparticles: Agents For Noninvasive Cancer Therapy
8. A potent causative agent of dental flourosis: Fluoride
9. Another causative agent of adult onset asthma : Atopy
10. Revelation Of Cancer Agent Could Help In Developing Effective Cancer Drugs
11. Sunitinib a Promising Agent for Treatment of Renal Cell Cancer
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |